Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

softwares

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

Baxter plans to file long-acting Advate in EU next year

Patients experienced a 95% reduction in bleeds

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

Takeda’s ‘oral Velcade’ clears first phase III hurdle

Ixazomib shows early stage promise for myeloma

How the focus on patient outcomes has allowed FMCG to enter into healthcare market

Associate Consultant Mette Drabæk talks about how the increase in ability to measure real-world patient outcomes has strengthened the position of the payer when negotiating reimbursement contracts with pharma companies.

Blue Latitude Health

- PMLiVE

Clinical data sharing ‘should be the norm’, says IoM

US Institute pitches into clinical data transparency debate

Top 7 Trends in Pharma Marketing for 2015

Toward the end of 2014 the Blue Latitude team gathered together for breakfast in the boardroom to discuss how pharma marketing will change in the year ahead and what trends...

Blue Latitude Health

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links